During 2017 closely held Synlogic Inc. did a reverse merger with publicly traded Mirna Therapeutics Inc (NASDAQ:MIRN) with MiRNA delisted as of August 2017 replacedby Synlogic (NASDAQ:SYBX) - not an SBIR-involved firm. Mirna’s lead product candidate, MRX34, had been the first microRNA mimic to enter clinical development in oncology, was studied as a single agent in a multicenter Phase 1 clinical trial, which included patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is underexpressed in a wide variety of cancers. MRX34 entered clinical testing in 2013. In September 2016, Mirna voluntarily halted enrollment and dosing in the clinical study following multiple immune-related severe adverse events (SAEs) observed in patients dosed with MRX34 over the course of the trial
